Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

When working with Active Directory groups, a common requirement is to enumerate all members of several different groups. This is done to typically figure out what kind of permissions each user in that ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Indeed, Nvidia tends to play the long game with its ...

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...